Liminatus Pharma Finalizes Highly Dilutive $3.46M Offering, Significantly Below Prior Target, Amidst Delisting Concerns
LIMN sits 20% above its 52-week low of $0.225 on elevated volume (1.9× avg).
Summary
Liminatus Pharma finalized a highly dilutive $3.46 million public offering, a significant reduction from its initial $9.0 million target, further highlighting its financial distress and Nasdaq delisting risks.
Key Events · Financing and Capital Events · LIMN
-
Finalized Public Offering Terms
The company is offering 8,270,000 shares of common stock (or pre-funded warrants) and 13,813,000 accompanying warrants to purchase 20,719,500 shares of common stock, at a combined price of $0.29 per unit. This finalizes terms of the offering initiated with the S-1 filing on February 11, 2026.
-
Significant Reduction in Capital Raise
Net proceeds are estimated at $3.46 million, a substantial decrease from the $9.0 million offering initially registered on February 11, 2026, indicating difficulty in securing the full target amount.
-
High Dilution for Shareholders
The offering will increase outstanding common stock by approximately 44.48% (from 31,064,633 to 44,877,633 shares, excluding warrant exercises), resulting in significant dilution for existing shareholders.
-
Ongoing Financial Distress and Delisting Risk
The company continues to operate with "substantial doubt about its ability to continue as a going concern" and faces Nasdaq delisting for failing to maintain a minimum $1 bid price, which this $0.29 offering does not address.
Analysis · LIMN · Life Sciences
Liminatus Pharma, a pre-clinical stage biopharmaceutical company, has finalized a public offering of common stock and warrants, aiming to raise approximately $3.46 million in net proceeds. This amount is substantially lower than the $9.0 million offering initially registered in the S-1 filing on February 11, 2026, indicating significant challenges in securing the desired capital. The offering is highly dilutive, increasing outstanding shares by over 44% (excluding warrant exercises), and is priced at $0.29 per share, which is below the Nasdaq minimum bid price of $1.00, for which the company received a delisting notice on January 26, 2026. The company explicitly states "substantial doubt about its ability to continue as a going concern," making this capital raise critical for its short-term operations but insufficient for long-term stability. The reduced proceeds and ongoing financial distress underscore the precarious position of the company.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIMN was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.23 to $33.66. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.